01 5Forlax
02 1Fortrans
03 3Fortrans/Eziclen
04 2Movicol
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 34
2019 Revenue in Millions : 45
Growth (%) : -24
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 47
2019 Revenue in Millions : 51
Growth (%) : -7
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 40
2020 Revenue in Millions : 47
Growth (%) : -8
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 40
2020 Revenue in Millions : 34
Growth (%) : 28
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 71
2021 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 35
2022 Revenue in Millions : 44
Growth (%) : -12
Macrogol (aka polyethlene glycol)
Main Therapeutic Indication : Others
Currency : USD
2015 Revenue in Millions : 43
2014 Revenue in Millions : 44
Growth (%) : 2%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 24
2015 Revenue in Millions : 25
Growth (%) : -4
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 41
2015 Revenue in Millions : 42
Growth (%) : -3
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 40
2018 Revenue in Millions : 34
Growth (%) : 17
LOOKING FOR A SUPPLIER?
